Log in
NYSE:HAE

Haemonetics Stock Forecast, Price & News

$106.95
+0.33 (+0.31 %)
(As of 10/23/2020 12:00 AM ET)
Add
Compare
Today's Range
$105.77
Now: $106.95
$107.01
50-Day Range
$82.88
MA: $90.54
$106.62
52-Week Range
$63.41
Now: $106.95
$130.75
Volume349,877 shs
Average Volume578,811 shs
Market Capitalization$5.42 billion
P/E Ratio57.81
Dividend YieldN/A
Beta0.57
Haemonetics Corporation, a healthcare company, provides hematology products and solutions. It operates through three segments: Plasma, Blood Center, and Hospital. The company offers automated plasma collection devices, related disposables, and software, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx and El-Dorado Donor donation and blood unit management systems; Hemasphere software that provides support for blood drive planning; and Donor Doc and e-Donor software to enhance the donor recruitment and retention. In addition, the company offers hospital products comprising TEG diagnostic systems that enables clinicians to assess the coagulation status of a patient at the point-of-care or laboratory setting; TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions; Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and BloodTrack, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. It markets and sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.
Read More
Haemonetics logo

Beat the Market (BTM) Rank

Analyst Opinion: 1.4Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.9 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.30 out of 5 stars

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Supplies
SectorMedical
CUSIP40502410
Phone781-848-7100
Employees3,004

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$988.48 million
Cash Flow$6.50 per share
Book Value$11.67 per share

Profitability

Net Income$76.53 million

Miscellaneous

Market Cap$5.42 billion
Next Earnings Date11/4/2020 (Confirmed)
OptionableOptionable
$106.95
+0.33 (+0.31 %)
(As of 10/23/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive HAE News and Ratings via Email

Sign-up to receive the latest news and ratings for HAE and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Haemonetics (NYSE:HAE) Frequently Asked Questions

How has Haemonetics' stock been impacted by COVID-19 (Coronavirus)?

Haemonetics' stock was trading at $103.72 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, HAE stock has increased by 3.1% and is now trading at $106.95.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Haemonetics?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Haemonetics in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Haemonetics
.

When is Haemonetics' next earnings date?

Haemonetics is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for Haemonetics
.

How can I listen to Haemonetics' earnings call?

Haemonetics will be holding an earnings conference call on Wednesday, November 4th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Haemonetics' earnings last quarter?

Haemonetics Co. (NYSE:HAE) announced its quarterly earnings results on Tuesday, August, 4th. The medical instruments supplier reported $0.46 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $0.41 by $0.05. The medical instruments supplier earned $195.60 million during the quarter, compared to analysts' expectations of $198.27 million. Haemonetics had a return on equity of 25.98% and a net margin of 10.10%. Haemonetics's revenue was down 18.0% compared to the same quarter last year. During the same period in the previous year, the company posted $0.81 earnings per share.
View Haemonetics' earnings history
.

What price target have analysts set for HAE?

5 analysts have issued 1 year price targets for Haemonetics' shares. Their forecasts range from $100.00 to $141.00. On average, they expect Haemonetics' stock price to reach $117.50 in the next year. This suggests a possible upside of 9.9% from the stock's current price.
View analysts' price targets for Haemonetics
.

Are investors shorting Haemonetics?

Haemonetics saw a drop in short interest in September. As of September 15th, there was short interest totaling 1,170,000 shares, a drop of 20.9% from the August 31st total of 1,480,000 shares. Based on an average daily trading volume, of 662,400 shares, the short-interest ratio is currently 1.8 days. Approximately 2.3% of the company's stock are sold short.
View Haemonetics' Short Interest
.

Who are some of Haemonetics' key competitors?

What other stocks do shareholders of Haemonetics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Haemonetics investors own include NVIDIA (NVDA), Micron Technology (MU), Johnson & Johnson (JNJ), AbbVie (ABBV), Citigroup (C), Align Technology (ALGN), Apache (APA), Chipotle Mexican Grill (CMG), Netflix (NFLX) and Pfizer (PFE).

Who are Haemonetics' key executives?

Haemonetics' management team includes the following people:
  • Mr. Christopher A. Simon, CEO, Pres & Director (Age 56, Pay $2.53M)
  • Mr. William P. Burke, CFO & Exec. VP (Age 52, Pay $1.1M)
  • Ms. Michelle L. Basil, Exec. VP, Gen. Counsel & Sec. (Age 48, Pay $968.85k)
  • Ms. Jacqueline D. Scanlan, Sr. VP of HR (Age 47, Pay $792.1k)
  • Mr. Josep Lluis Llorens, Sr. VP of Global Manufacturing & Supply Chain (Age 58, Pay $826.89k)

What is Haemonetics' stock symbol?

Haemonetics trades on the New York Stock Exchange (NYSE) under the ticker symbol "HAE."

Who are Haemonetics' major shareholders?

Haemonetics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Boston Trust Walden Corp (0.50%), Summit Creek Advisors LLC (0.26%), Retirement Systems of Alabama (0.24%), Deltec Asset Management LLC (0.06%), Envestnet Asset Management Inc. (0.05%) and Assenagon Asset Management S.A. (0.03%). Company insiders that own Haemonetics stock include Christopher Simon, Dan Goldstein, Jacqueline Scanlan, Josep Llorens, Mark W Kroll, Michelle L Basil, Neil Mr Ryding, Pedro P Granadillo, Richard J Meelia, Ronald G Gelbman, Said Bolorforosh and William P Mr Burke.
View institutional ownership trends for Haemonetics
.

Which institutional investors are selling Haemonetics stock?

HAE stock was sold by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., State of Alaska Department of Revenue, Baldwin Brothers Inc. MA, and Crossmark Global Holdings Inc.. Company insiders that have sold Haemonetics company stock in the last year include Christopher Simon, Dan Goldstein, Jacqueline Scanlan, Josep Llorens, Mark W Kroll, Michelle L Basil, Ronald G Gelbman, Said Bolorforosh, and William P Mr Burke.
View insider buying and selling activity for Haemonetics
.

Which institutional investors are buying Haemonetics stock?

HAE stock was purchased by a variety of institutional investors in the last quarter, including Boston Trust Walden Corp, Deltec Asset Management LLC, Pacer Advisors Inc., Envestnet Asset Management Inc., Summit Creek Advisors LLC, First Hawaiian Bank, Vestmark Advisory Solutions Inc., and Exane Derivatives.
View insider buying and selling activity for Haemonetics
.

How do I buy shares of Haemonetics?

Shares of HAE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Haemonetics' stock price today?

One share of HAE stock can currently be purchased for approximately $106.95.

How big of a company is Haemonetics?

Haemonetics has a market capitalization of $5.42 billion and generates $988.48 million in revenue each year. The medical instruments supplier earns $76.53 million in net income (profit) each year or $3.31 on an earnings per share basis. Haemonetics employs 3,004 workers across the globe.

What is Haemonetics' official website?

The official website for Haemonetics is www.haemonetics.com.

How can I contact Haemonetics?

Haemonetics' mailing address is 125 Summer Street, Boston MA, 02110. The medical instruments supplier can be reached via phone at 781-848-7100 or via email at [email protected]

This page was last updated on 10/24/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.